Cardiac Myosin

Other Cytoskeletal Signaling Related Inhibitors

HSP Kinesin Microtubule Associated Integrin PAK Dynamin MLCK TACC3 Gap-Junction Actin

Cat.No.	Product Name	Information	Product Use Citations
S9948	Danicamtiv (MYK-491)	A novel cardiac myosin activator that enhances cardiomyocyte contraction, Danicamtiv (MYK-491, SAR 440181) is also known by this designation.	Journal of the American Heart Association, October 7, 2023, 12(20):e030682 Journal of General Physiology, June 18, 2025, 157(4):e202513762 Journal of General Physiology, July 7, 2025, e202513762
S8861	MYK-461 (Mavacamten)	Mavacamten (MYK-461, SAR439152) is a small-molecule modulator of cardiac myosin that targets the underlying sarcomere hypercontractility of hypertrophic cardiomyopathy (HCM), one of the most prevalent heritable cardiovascular disorders.	Frontiers in Cardiovascular Medicine, February 20, 2023, 1105257 European Heart Journal, 2025, ehaf813 Eur Heart J, 2025, ehaf813
E4662	CK-586	CK-586(CK-4021586) is an inhibitor of cardiac myosin used to treat obstructive hypertrophic cardiomyopathy (oHCM). It effectively reduces left ventricular outflow tract obstruction (LVOTO) in a dose-dependent manner.
E1016	Aficamten (CK-274)	Aficamten (CK-274, CK 3773274) is a novel cardiac myosin inhibitor that reduces myocardial contractility in vitro and in vivo with an IC50 of 1.4 μM.